AML antigens and uses thereof
The present invention provides novel compounds comprising an antigen of AML cells, and uses thereof.
1. A recombinant or purified CD43 peptide for AT14-013 antibody binding, said peptide comprising:
the amino acid sequence of SEQ ID NO 3, wherein said peptide has an AML-specific glycosylation pattern or an MDS-specific glycosylation pattern, and wherein the peptide is coupled to a molecular scaffold or a carrier.
2. The peptide of claim 1 , said peptide comprising sialic acid residues.
3. The peptide of claim 2 , wherein said peptide is neuramidase-sensitive.
4. The recombinant or purified CD43 peptide of claim 1 , wherein said peptide is in the context of an MHC complex.
5. An immunogenic composition comprising the CD43 peptide of claim 1 .
6. The immunogenic composition of claim 5 , wherein said composition is a pharmaceutical composition, said pharmaceutical composition further comprising: a pharmaceutically acceptable carrier, diluent or excipient.
7. A diagnostic kit comprising the CD43 peptide of claim 1 .
8. A recombinant or purified CD43 peptide for AT14-013 antibody binding, said peptide comprising:
the amino acid sequence of SEQ ID NO 3, wherein said peptide has an AML-specific glycosylation pattern or an MDS-specific glycosylation pattern, and wherein the peptide is coupled to a molecular scaffold or a carrier;
wherein the peptide is coupled to keyhole limpet hemocyanin or a CLIPS scaffold.
9. The peptide of claim 8 , wherein the CLIPS scaffold is bis(bromomethyl)benzene, tris(bromomethyl)benzene or tetra(bromomethyl)benzene.